Closed Fracture of Hip
Conditions
Keywords
proximal, hip, fractures
Brief summary
This is a randomized controlled trial comparing the use of tranexamic acid to placebo in patients admitted to hospital with a hip fracture.
Detailed description
1. transfusion of allogeneic RBC's is not free of adverse events and has been associated with an increased risk of postoperative infection 2. Tranexamic acid in trauma patients has been shown to reduce 30-day mortality. Hospital trauma protocol includes tranexamic acid in patients with major bleeding. 3. Tranexamic acid in orthopedic elective joint reconstruction surgery has been shown to substantially decrease bleeding in knee and hip arthroplasty. 4. in hip fracture surgery, transexamic acid reduces erythrocyte transfusion rate but may promote a hypercoagulable state. 5. Tranexamic acid is an antifibrinolytic drug that inhibits plasminogen from turning into plasmin thereby inhibiting clot breakdown.
Interventions
DRUGTranexamic acid
GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours. GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours. Group C - A control group will only receive placebo in the emergency room and in the OR.
Sponsors
Tel-Aviv Sourasky Medical Center
Michal Roll PhD,MBA
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted to the emergency room with proximal hip fractures (31A-31B according to the Muller AO classification of fractures - long bones). * Patients mentally capable of giving informed consent.
Exclusion criteria
1. Vascular events within the last 2 months such as CVA, TIA, ACS, MI, DVT or arterial thrombosis. 2. Patients receiving anticoagulation therapy with Coumadin or Plavix. 3. Pregnancy and breastfeeding females. 4. Previous arterial or venous thrombosis 5. History of seizures. 6. Creatinine \>2. 7. Oestroprogestive therapy. 8. Multiple fractures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total amount of blood loss per patient from admission to day 5 post-op | 5 DAYS |
Secondary
| Measure | Time frame |
|---|---|
| Number of packed cell transfusion per patient. | 5 DAYS |
| Initial functional outcome and feeling of well-being. | 5 days |
| thromboembolic events | 5 days |
| post-operative bacterial infection | 5 days |
| 30 day mortality rate | 30 days |
Countries
Israel
Outcome results
None listed